{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:15:10Z","timestamp":1764494110734,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,9,16]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>A 45-year-old woman was admitted for diabetic ketoacidosis (DKA). Aggressive rehydration and continuous intravenous insulin resulted in improved blood glucose levels; however, metabolic acidosis persisted. One day prior to admission, the patient took a single dose of a sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor and this likely contributed to the prolonged euglycemic DKA. A single dose of this drug remained effective for over 100\u2009hours as evidenced by massive excretion of urine glucose continuing long after blood glucose normalisation. SGLT2 inhibitor use should be refrained in cases in which DKA has already occurred as they may result in increasing severity or prolonged DKA.<\/jats:p>","DOI":"10.1136\/bcr-2020-235969","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T17:30:25Z","timestamp":1602091825000},"page":"e235969","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium\u2013glucose cotransporter 2 inhibitor"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7013-9863","authenticated-orcid":false,"given":"Maki","family":"Miwa","sequence":"first","affiliation":[{"name":"Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Shibuya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikio","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Shibuya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Kaszynski","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Shibuya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Goto","sequence":"additional","affiliation":[{"name":"Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, Shibuya-ku, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"2025082710035130000_13.10.e235969.1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307"},{"key":"2025082710035130000_13.10.e235969.2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.mcna.2016.12.011","article-title":"Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state","volume":"101","author":"Fayfman","year":"2017","journal-title":"Med Clin North Am"},{"key":"2025082710035130000_13.10.e235969.3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40261-019-00794-5","article-title":"Adverse drug reaction profile of SGLT2 inhibitor-associated diabetic Ketosis\/Ketoacidosis in Singapore and their precipitating factors","volume":"39","author":"Limenta","year":"2019","journal-title":"Clin Drug Investig"},{"key":"2025082710035130000_13.10.e235969.4","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0843"},{"key":"2025082710035130000_13.10.e235969.5","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2924"},{"key":"2025082710035130000_13.10.e235969.6","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"Sglt2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"key":"2025082710035130000_13.10.e235969.7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13017","article-title":"Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP\/LT)","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2025082710035130000_13.10.e235969.8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/dom.12957","article-title":"Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP\/INS): results of a 16-week randomized, double-blind, placebo-controlled multicentre trial","volume":"19","author":"Terauchi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025082710035130000_13.10.e235969.9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00007"},{"key":"2025082710035130000_13.10.e235969.10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0043-104779","article-title":"Pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in healthy male subjects","volume":"67","author":"Kasahara-Ito","year":"2017","journal-title":"Drug Res"},{"key":"2025082710035130000_13.10.e235969.11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11239-017-1607-9","article-title":"Efficacy and safety of outpatient treatment with direct oral anticoagulation in pulmonary embolism","volume":"45","author":"Ghazvinian","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2025082710035130000_13.10.e235969.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3180"},{"key":"2025082710035130000_13.10.e235969.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3828"},{"key":"2025082710035130000_13.10.e235969.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12245-019-0240-0","article-title":"Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature","volume":"12","author":"Diaz-Ramos","year":"2019","journal-title":"Int J Emerg Med"},{"key":"2025082710035130000_13.10.e235969.15","article-title":"Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis","volume":"11","author":"Iqbal","year":"2019","journal-title":"Cureus"},{"key":"2025082710035130000_13.10.e235969.16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-215340","article-title":"Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin","volume":"2016","author":"Rashid","year":"2016","journal-title":"BMJ Case Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-235969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:03:58Z","timestamp":1756314238000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-235969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":16,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,7]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/bcr-2020-235969"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-235969","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}